Amgen Inc (AMGN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Amgen ( AMGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Amgen rose $2.06 (2.0%) to $104.24 on average volume. Throughout the day, 3,376,775 shares of Amgen exchanged hands as compared to its average daily volume of 4,346,500 shares. The stock ranged in a price between $102.45-$104.68 after having opened the day at $102.45 as compared to the previous trading day's close of $102.18. Other companies within the Health Care sector that increased today were: Durect Corporation ( DRRX), up 17.3%, Cormedix ( CRMD), up 15.1%, Unilife Corporation ( UNIS), up 14.2% and Affymax ( AFFY), up 14.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $79.2 billion and is part of the drugs industry. The company has a P/E ratio of 17.8, above the S&P 500 P/E ratio of 17.7. Shares are up 22.5% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Bovie Medical Corporation ( BVX), down 9.9%, Peregrine Pharmaceuticals ( PPHM), down 9.3%, Edap TMS ( EDAP), down 8.6% and MediciNova ( MNOV), down 7.0% , were all laggards within the health care sector with Questcor Pharmaceuticals ( QCOR) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback